Xarelto Articles
Brazil's atrial fibrillation market to grow at 31% annually over the next five years
19 December 2012
Use of low-molecular-weight heparins and vitamin K antagonists for VTE set for sharp decline as oral agents roll out
21 November 2012
Bayer's Xarelto gets EU clearance for PE and prevention of DVT; gives up on Schiff acquisition
21 November 2012
Bayer initiates Ph III trail of Xarelto in cardiac event prevention; R&D day presentation
14 November 2012
Atrial fibrillation drug market will grow from $2.7 billion in 2011 to $9.2 billion in 2021
13 November 2012
Good news from CHMP for Astellas, Savient, Bayer and Abbott, but not for Lundbeck and Merz
22 October 2012
Janssen responds to FDA's Xarelto CRL; resubmits sNDA
10 September 2012
Bayer and J&J's Xarelto aids survival after heart attack
27 August 2012
Reduced incidence of mortality is greatest unmet need in post-myocardial infarction, say US cardiologists and MCOs
18 June 2012
Roche returns rights to TB-403 to ThromboGenics and BioInvent, who abandon TB-402 development
5 June 2012
News briefs on Janssen, Bayer and Merck KGaA/Threshold
12 April 2012
UK NICE asks Bayer for Xarelto cost-effectiveness data
13 March 2012
Bayer and J&J’s Xarelto gets US Priority Review for new indication
29 February 2012
Bayer’s Xarelto gets backing in Scotland
14 February 2012
Bayer and Algeta’s Alpharadin efficacy confirmed; Almirall to market Xarelto in Spain
13 February 2012
Bayer’s Xarelto OKed in Japan; promising regorafenib data
19 January 2012
Bayer boasts four potential pipeline blockbusters
21 December 2011
EU backs Bayer’s Xarelto for stroke prevention
20 December 2011
Outlook for VTE treatment and prophylaxis market
14 December 2011
Bayer’s Xarelto significantly reduced mortality in major ACS study; Bristol-Myers’ Eliquis fails endpoint in VTE trial
14 November 2011
US FDA clears Bayer/Johnson & Johnson’s Xarelto for stroke risk reduction in AF patients
7 November 2011
Atrial fibrillation drug market to increase nearly eight-fold to over $10 billion in 2020
20 October 2011
Disappointing FDA briefing papers on Bayer/J&J’s Xarelto
7 September 2011
US FDA approves Bayer and J&J’s Xarelto to help prevent DVT following hip/knee replacement surgery
4 July 2011
Bayer/Ortho-McNeil’s VTE drug Xarelto will earn peak-year sales of $500 million to $1 billion
17 May 2011
Mixed MAGELLAN study data on Bayer and J&J’s Xarelto call into question blockbuster potential
8 April 2011
Crucell M&A update; Meda buys Antula; Bayer eyes pharma boost
22 February 2011
Bayer files for EU approval of anticoagulant rivaroxaban for stroke prevention; updates on US filing
6 January 2011
Bayer says it has well-stocked product pipeline, spending more than $4 billion on R&D
9 December 2010
Landmark double-blind ROCKET AF study shows Bayer/J&J’s Xarelto is better than warfarin
16 November 2010
New Zealand’s PHARMAC enters deal with InterPharma for seven cancer drugs and with Bayer over Xarelto, Avelox and Copaxone
10 November 2010
US FDA advisory backs Boehringer Ingelheim’s Pradaxa, putting firm ahead in the race to get new blood thinner on US market
21 September 2010
Two blockbuster potential stroke/DVT drugs report good results at ESC Congress: Bristol-Myers/Pfizer’s apixaban and Bayer/J&J’s rivaroxaban
1 September 2010
Research briefs on Merck & Co’s boceprevir and Bayer’s Xarelto; legal updates from AstraZeneca and Daiichi Sankyo/Actavis
5 August 2010
Novel oral anticoagulants will drive venous thromboembolism market to nearly double by 2018
1 April 2010
Showing 1-70 of 70 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
